"B 663" IN THE TREATMENT OF LEPROSY - Preliminary Report of a Pilot Trial

Browne, S. G.; Hogerzeil, L. M.

doi:10.5935/0305-7518.19620002

Cited by 55 publications

(47 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2 This was followed by other firstline drugs, such as clofazimine 3 in 1962 and rifampin 4 in 1970. Dapsone-resistant leprosy was first proved by Petit and Rees in 1964, 5 while resistance to rifampin 6 and to clofazimine 7 was subsequently reported.…”

Section: Introductionmentioning

confidence: 98%

In-vitro activity of sitafloxacin (DU-6859a), either singly or in combination with rifampin analogs, against Mycobacterium leprae

Dhople

Namba

2003

Journal of Infection and Chemotherapy

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 98%

In-vitro activity of sitafloxacin (DU-6859a), either singly or in combination with rifampin analogs, against Mycobacterium leprae

Dhople

Namba

2003

Journal of Infection and Chemotherapy

View full text Add to dashboard Cite

“…Fortunately, additional antimicrobial agents such as rifampin and clofazimine were developed and introduced for the treatment of leprosy (44,232). Although rifampin proved to be a powerful antileprosy drug, use of rifampin alone or in combination with dapsone for the treatment of dapsone-resistant leprosy led to the rapid development of rifampin-resistant or- ganisms (137,177).…”

Section: Chemotherapy Current Therapies and Drug Resistancementioning

confidence: 99%

The Continuing Challenges of Leprosy

et al. 2006

View full text Add to dashboard Cite

SUMMARY Leprosy is best understood as two conjoined diseases. The first is a chronic mycobacterial infection that elicits an extraordinary range of cellular immune responses in humans. The second is a peripheral neuropathy that is initiated by the infection and the accompanying immunological events. The infection is curable but not preventable, and leprosy remains a major global health problem, especially in the developing world, publicity to the contrary notwithstanding. Mycobacterium leprae remains noncultivable, and for over a century leprosy has presented major challenges in the fields of microbiology, pathology, immunology, and genetics; it continues to do so today. This review focuses on recent advances in our understanding of M. leprae and the host response to it, especially concerning molecular identification of M. leprae, knowledge of its genome, transcriptome, and proteome, its mechanisms of microbial resistance, and recognition of strains by variable-number tandem repeat analysis. Advances in experimental models include studies in gene knockout mice and the development of molecular techniques to explore the armadillo model. In clinical studies, notable progress has been made concerning the immunology and immunopathology of leprosy, the genetics of human resistance, mechanisms of nerve injury, and chemotherapy. In nearly all of these areas, however, leprosy remains poorly understood compared to other major bacterial diseases.

show abstract

“…Elle a été d'abord proposée comme antituberculeux avant de se révéler aussi efficace que la dapsone pour le traitement de la lèpre [8].…”

Section: La Clofazimineunclassified